Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 121 to 135 of 538 results for syndrome

  1. Auto- versus fixed-level CPAP for OSAHS: What is the clinical and cost effectiveness of auto- and fixed-level continuous positive airway pressure (CPAP) for managing mild obstructive sleep apnoea/hypopnoea syndrome (OSAHS)?

    airway pressure (CPAP) for managing mild obstructive sleep apnoea/hypopnoea syndrome (OSAHS)? Any explanatory notes(if applicable) For a...

  2. Diagnostic tests: What diagnostic tests are clinically and cost effective in people with suspected myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome (ME/CFS)?

    suspected myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome (ME/CFS)? Any explanatory notes(if applicable) For a...

  3. What is the effectiveness and safety of sacral nerve stimulation and transanal irrigation compared to symptomatic treatment for people with major low anterior resection syndrome?

    compared to symptomatic treatment for people with major low anterior resection syndrome? Any explanatory notes(if applicable) Why the...

  4. Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality (TA322)

    Evidence-based recommendations on lenalidomide (Revlimid) for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality in adults.

  5. What is the most effective management strategy for preventing the development of excessive weight gain and metabolic syndrome associated with the use of antipsychotic medication in children and young people?

    strategy for preventing the development of excessive weight gain and metabolic syndrome associated with the use of antipsychotic...

  6. Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia (TA561)

    Evidence-based recommendations on venetoclax (Venclyxto) with rituximab for previously treated chronic lymphocytic leukaemia in adults.

  7. Patient decision aids

    guide outlines how we develop our PDAs. PDAs by condition Cancer Lynch syndrome: should I take aspirin to reduce my chance of getting...

  8. Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome (TA335)

    Evidence-based recommendations on rivaroxaban (Xarelto) for preventing atherothrombotic events, such as heart attack and stroke, after acute coronary syndrome in adults.

  9. Serial transverse enteroplasty procedure (STEP) for bowel lengthening in parenteral nutrition-dependent children (HTG149)

    Evidence-based recommendations on the serial transverse enteroplasty procedure (STEP) for bowel lengthening in parenteral nutrition-dependent children. This involves cutting and stapling the bowel in a zig-zag pattern to narrow and lengthen it.

  10. Prioritisation board decisions 2025

    Our centralised approach to prioritising our guidance topics ensures that we produce guidance that's relevant, timely, accessible, and has demonstrable impact.

  11. Intrapartum care for women with existing medical conditions or obstetric complications and their babies (NG121)

    This guideline covers care during labour and birth for women who need extra support because they have a medical condition or complications in their current or previous pregnancy. The guideline also covers women who have had no antenatal care. It aims to improve experiences and outcomes for women and their babies.

  12. Obinutuzumab for treating childhood-onset idiopathic nephrotic syndrome in people 2 years and over [ID6692]

    Awaiting development Reference number: GID-TA11910 Expected publication date: TBC

  13. Sacral nerve stimulation for idiopathic chronic non-obstructive urinary retention (HTG391)

    Evidence-based recommendations on sacral nerve stimulation for idiopathic chronic non-obstructive urinary retention. This involves implanting a stimulator device into the upper buttock to restore the ability to empty the bladder voluntarily.

  14. Multiple sclerosis in adults: management (NG220)

    This guideline covers diagnosing and managing multiple sclerosis in people aged 18 and over. It aims to improve the quality of life for people with multiple sclerosis by promoting prompt and effective symptom management and relapse treatment, and comprehensive reviews.

  15. Somapacitan for treating growth failure caused by Turner syndrome in people 2 to 17 years [ID6621]

    Awaiting development Reference number: GID-TA11821 Expected publication date: TBC